Results 221 to 230 of about 101,068 (248)

Rethinking venous thromboembolism risk after major orthopedic surgery: a transient threat or a persistent problem? [PDF]

Res Pract Thromb Haemost
Story CM, Merz LE, Schaefer JK.
europepmc   +1 more source

Facts and Misfacts on D‐Dimer Testing. Consensus Guidance From the Italian Society on Thrombosis and Hemostasis (SISET)

American Journal of Hematology, Volume 101, Issue 1, Page 97-109, January 2026.
ABSTRACT D‐dimer defines degradation products derived from the proteolysis mediated by plasmin on cross‐linked fibrin. The evidence‐based use of D‐dimer in some conditions has been consolidated. Currently, however, there is an entrenched prescription of D‐dimer testing to screen otherwise healthy subjects that may induce prescribing physicians to start
Armando Tripodi, Walter Ageno, Luca Barcella, Antonio Coppola, Marcello Di Nisio, Massimo Franchini, Monia Marchetti, Rossella Marcucci, Marco Marietta, Pasquale Pignatelli, Domenico Prisco, Valerio De Stefano   +11 more
wiley   +1 more source

Burden and management of venous thromboembolism in children and adolescents (2004-2023): a Swiss nationwide epidemiological study. [PDF]

Eur J Pediatr
Wolf S, Albisetti M, Bosch A, Cannegieter SC, Klok FA, Trinchero A, Valerio L, Kucher N, Barco S.   +8 more
europepmc   +1 more source

Outcomes of Cerebral Venous Thrombosis in Patients With Myeloproliferative Neoplasms from a U.S. Nationwide Hospitalization Study

eJHaem, Volume 7, Issue 1, February 2026.
Nikhil Vojjala, Raj Shah, Viktoriya Gibatova, Lakshmi Kattamuri, Shubham Agrawal, Geetha Krishnamoorthy, Rushad Patell   +6 more
wiley   +1 more source

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations

American Journal of Hematology, Volume 101, Issue 1, Page 41-55, January 2026.
ABSTRACT Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma. The success of asparaginase‐containing regimens has led to trials of pediatric/pediatric‐inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations with acute ...
Ibrahim Aldoss, Amir Ali, Ryan D. Cassaday, Emily K. Curran, Marlise R. Luskin, Luke D. Maese, Etan Orgel, Dan Douer   +7 more
wiley   +1 more source

The balancing act after pediatric venous thromboembolism. [PDF]

Blood Adv
Whitworth H, Raffini L.
europepmc   +1 more source

A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study

American Journal of Hematology, Volume 101, Issue 1, Page 79-88, January 2026.
The WAVe stdudy‐ A multicenter prospective cohort study of wieght‐adjusted dalteparin in patients over 90 kg with acute cancer‐associated venous thromboembolism. ABSTRACT Patients with cancer‐associated thrombosis (CAT) are commonly treated with low‐molecular‐weight heparin (LMWH), but whether dose capping is needed in patients over 90 kg is unclear ...
Tzu‐Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D'Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier   +14 more
wiley   +1 more source

Delayed Venous Thromboembolism Diagnosis and Mortality Risk.

JAMA Netw Open
Kang MJ, Schreiber R, Baris VK, Chang F, Hijjawi S, Kim A, Novoa-Laurentiev J, Nye T, Lipsitz S, Nawab K, Sainlaire M, Song W, Syrowatka A, Piazza G, Thai T, Zhou L, Samal L, Bates DW, Dykes PC.   +18 more
europepmc   +1 more source

Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study. [PDF]

Clin Appl Thromb Hemost
Chen Z, Wang S, Wang Y.
europepmc   +1 more source